Radiation zaps lingering brain tumors in lung cancer patients

NCT ID NCT06020066

Ongoing Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding precise radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with non-small cell lung cancer. Participants have brain tumors that remain after 3-6 months of a targeted drug. The goal is to see if the combination delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic radiotherapy (precise radiation beams)
What this could lead to: If successful, this approach could help control brain metastases in lung cancer patients, potentially delaying disease progression and improving survival without needing stronger drugs.
What could go wrong: This is a Phase 2 trial with 202 participants, so results are still preliminary. The added radiation may cause side effects like brain swelling or fatigue, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.